Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$582.31B+168.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hiroyuki Okuzawa
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 20,171
- Beta
- 0.14
- Country
- JP
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.92
Financials
Revenue
$582.31B+168.3%Net Income
$69.54B+278.2%EBITDA
$107.92B+184.8%Free Cash Flow
$-17.13B-176.3%EPS (diluted)
$38.75+327.7%Shares Outstanding (diluted)
1.82B-10.3%Operating Expenses
$370.23BCash & Debt
$633.64BReturn of Capital
$72.16BDividend per Share
$0.31Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $2.25T | $275.55B | $148.60 |
| 2025 | $1.89T | $295.76B | $155.96 |
| 2024 | $1.60T | $200.73B | $104.69 |
| 2023 | $1.28T | $109.19B | $56.96 |
| 2022 | $1.04T | $66.97B | $34.94 |
| 2021 | $962.52B | $75.96B | $39.17 |
| 2020 | $981.79B | $129.07B | $66.40 |
| 2019 | $929.72B | $93.41B | $48.07 |
| 2018 | $960.20B | $60.28B | $30.44 |
| 2017 | $955.12B | $53.47B | $26.54 |
| 2016 | $986.45B | $82.28B | $39.79 |
| 2015 | $919.37B | $322.12B | $152.52 |
| 2014 | $1.12T | $60.94B | $28.86 |
| 2013 | $997.85B | $66.62B | $31.55 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DSNKY's reported EPS growth of 12.7% a year over 13 years.
- EPS in 5 years
- $270.74
- Implied price
- $5,144
- Return from $17.37
- 212.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2,557 — today's price is already 99.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| 2.7% | 163.6% | 174.8% | 184.4% | 192.9% | 200.5% |
| 7.7% | 176.5% | 188.2% | 198.3% | 207.1% | 215.1% |
| 12.7% | 189.3% | 201.6% | 212.1% | 221.4% | 229.7% |
| 17.7% | 202.1% | 214.9% | 226.0% | 235.7% | 244.3% |
| 22.7% | 215.0% | 228.3% | 239.8% | 249.9% | 259.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
View source ↗
Earnings
Fri, Oct 30(in 3 weeks)
Consensus estimate $0.21 per share
Typical surprise +4.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.24 vs $0.25miss
- Mon, May 11$0.15 vs $0.33miss
- Fri, Jan 30$0.30 vs $0.25beat
- Fri, Oct 31$0.16 vs $0.30miss
- Thu, Jul 31$0.31 vs $0.23beat
- Fri, Apr 25$0.32 vs $0.14beat
Estimates and results for DSNKY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 15, 2025 (43d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.